The NeuroAiD II (MLC901) in vascular cognitive impairment study (NEURITES) for the NEURITE investigators

Cerebrovascular Diseases

Volumn 35, Issue SUPPL.1, 2013, Pages 23-29

  Chen, Christopher L H ^a   Ikram, Kamran ^b   Anqi, Qiu ^b   Yin, Wong Tien ^a   Chen, Annabel ^c   Venketasubramanian, Narayanaswamy ^b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^c NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

Author keywords

Cognitive impairment; MLC601; MLC901; NeuroAiD; Neurogenesis; Neuroplasticity; Neuroprotection; Stroke

Indexed keywords

HERBACEOUS AGENT; MLC 901; NEUROAID II; NEUROPROTECTIVE AGENT; PLACEBO; UNCLASSIFIED DRUG; ANGELICA ROOT; CHINESE DRUG; NOOTROPIC AGENT;

ADULT; AGED; ALZHEIMER DISEASE; ALZHEIMER DISEASE COOPERATIVE STUDY ACTIVITIES OF DAILY LIVING SCALE; ARTICLE; BECK DEPRESSION INVENTORY; BEHAVIOR; BRAIN PERFUSION; CEREBROVASCULAR DISEASE; CHINESE MEDICINE; COGNITIVE BATTERY; COGNITIVE DEFECT; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEPRESSION; DIFFUSION TENSOR IMAGING; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXECUTIVE FUNCTION; FEMALE; GERIATRIC DEPRESSION SCALE; HUMAN; LABORATORY TEST; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MILD COGNITIVE IMPAIRMENT; MULTIINFARCT DEMENTIA; NAUSEA; NERVE FUNCTION; NEUROIMAGING; NEUROPSYCHIATRIC INVENTORY; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NERVE; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RETINA; SPIN LABELING; VASCULAR COGNITIVE IMPAIRMENT NO DEMENTIA; VITAL SIGN; VOMITING; WHITE MATTER; BRAIN BLOOD FLOW; CELL PROLIFERATION; MINI MENTAL STATE EXAMINATION; NERVE CELL PLASTICITY; NEUROPROTECTION; PEACH; POLYGALACEAE; RANKIN SCALE; SAFFLOWER; WECHSLER INTELLIGENCE SCALE;

ACTIVITIES OF DAILY LIVING; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CEREBRAL ANGIOGRAPHY; CEREBROVASCULAR DISORDERS; COGNITION DISORDERS; DEPRESSION; DOUBLE-BLIND METHOD; DRUGS, CHINESE HERBAL; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; NEUROPSYCHOLOGICAL TESTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETINA; SAMPLE SIZE; STROKE; TREATMENT OUTCOME;

EID: 84875976090     PISSN: 10159770     EISSN: 14219786     Source Type: Journal    
DOI: 10.1159/000346234     Document Type: Article

References (24)

1. Jorm AF, O'Brien J: The epidemiology of vascular dementia: an overview and commentary; in O'Brien J, Ames D, Gustafson L, et al (eds): Cerebrovascular Disease, Cognitive Impairment and Dementia, ed 2. London, Martin Dunitz, 2004, pp 95-100.
2. Chen CP: Transcultural expression of subcortical vascular disease. J Neurol Sci 2004; 226: 45-47.
3. Rockwood K, Wentzel C, Hachinski V, Ho-gan DB, MacKnight C, McDowell I: Prevalence and outcomes of vascular cognitive impairment. Vascular Cognitive Impairment Investigators of the Canadian Study of Health and Aging. Neurology 2000; 54:447-451.
4. Wentzel C, Rockwood K, MacKnight C, Hachinski V, Hogan DB, Feldman H, Østbye T, Wolfson C, Gauthier S, Verreault R, McDowell I: Progression of impairment in patients with vascular cognitive impairment without dementia. Neurology 2001; 57:714-716.
5. Ritchie K, Touchon J: Mild cognitive impairment: conceptual basis and current nosologi-cal status. Lancet 2000; 355:225-228.
6. Tham W, Auchus AP, Thong M, Goh ML, Chang HM, Wong MC, Chen CP: Progression of cognitive impairment after stroke: one year results from a longitudinal study of Singaporean stroke patients. J Neurol Sci 2002; 203-204:49-52.
7. Narasimhalu K, Ang S, De Silva DA, Wong MC, Chang HM, Chia KS, Auchus AP, Chen C: Severity of CIND and MCI predict incidence of dementia in an ischemic stroke cohort. Neurology 2009; 73:1866-1872.
8. Narasimhalu K, Ang S, De Silva DA, Wong MC, Chang HM, Chia KS, Auchu AP, Chen C: The prognostic effects of CIND, CIND severity, and domain-specific cognitive impairments in an ischemic stroke cohort. Stroke 2011; 42:883-888.
9. Narasimhalu K, Effendy S, Sim CH, Lee JM, Chen I, Hia SB, Xue HL, Corrales M, Chang HM, Wong MC, Chen CP, Tan EK: Randomized controlled trial of rivastigmine in isch-emic stroke patients with CIND. Acta Neurol Scand 2010; 121:217-224.
10. Jokinen H, Kalska H, Mäntylä R, Pohjasvaara T, Ylikoski R, Hietanen M, Salonen O, Kaste M, Erkinjuntti T: Cognitive profile of subcortical ischaemic vascular disease. J Neurol Neurosurg Psychiatry 2006; 77:28-33.
11. Kandiah N, Narasimhalu K, Lee J, Chen CL: Differences exist in the cognitive profile of mild Alzheimer's disease and subcortical ischemic vascular dementia. Dement Geriatr Cogn Disord 2009; 27:399-403.
12. Heurteaux C, Gandin C, Borsotto M, et al: Neuroprotective and neuroproliferative activities of NeuroAiD (MLC601, MLC901), a Chinese medicine, in vitro and in vivo. Neu-ropharmacology 2010; 58:987-1001.
13. Quintard H, Borsotto M, Veyssiere J, et al: MLC901, a traditional Chinese medicine, protects the brain against global ischemia. Neuropharmacology 2011; 61:622-631.
14. Chen C, Venketasubramanian N, Gan RN, et al: Danqi Piantang Jiaonang (DJ), a traditional Chinese medicine, in poststroke recovery. Stroke 2009; 40:859-863.
15. Venketasubramanian N, Chen CL, Gan RN, Chan BP, Chang HM, Tan SB, Picard D, Na-varro JC, Baroque AC 2nd, Poungvarin N, Donnan GA, Bousser MG, CHIMES Investigators: A double-blind, placebo-controlled, randomized, multicentre study to investigate Chinese Medicine NeuroAiD Efficacy on Stroke recovery (CHIMES Study). Int J Stroke 2009; 4:54-60.
16. Gan R, Lambert C, Lianting J, Chan ESY, Venketasubramanian N, Chen C, et al: Danqi Piantang Jiaonang does not modify hemosta-sis, hematology, and biochemistry in normal subjects and stroke patients. Cerebrovasc Dis 2008; 25:450-456.
17. Young SHY, Zhao Y, Koh A, Singh R, Chan BPL, Chang HM, et al: Safety profile of MLC601 (NeuroAiD) in acute ischemic stroke patients: a Singaporean substudy of the Chinese Medicine NeuroAiD Efficacy on Stroke recovery study. Cerebrovasc Dis 2010; 30:1-6.
18. Bavasard Shahripour R, Shamsaei G, Pak-daman H, et al: The effect of NeuroAiD (MLC601) on cerebral blood flow velocity in subjects' post brain infarct in the middle cerebral artery territory. Eur J Intern Med 2011; 22:509-513.
19. Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C, Launer LJ, Laurent S, Lopez OL, Nyenhuis D, Petersen RC, Schneider JA, Tzourio C, Arnett DK, Bennett DA, Chui HC, Higashida RT, Lindquist R, Nilsson PM, Roman GC, Sellke FW, Seshadri S: Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011; 42:2672-2713.
20. Stinear C: Prediction of recovery of motor function after stroke. Lancet Neurol 2010; 9: 1228-1232.
21. Lesage SR, Mosley TH, Wong TY, Szklo M, Knopman D, Catellier DJ, Cole SR, Klein R, Coresh J, Coker LH, Sharrett AR: Retinal mi-crovascular abnormalities and cognitive decline: the ARIC 14-year follow-up study. Neurology 2009; 73:862-868.
22. Baker ML, Marino Larsen EK, Kuller LH, Klein R, Klein BE, Siscovick DS, Bernick C, Manolio TA, Wong TY: Retinal microvascu-lar signs, cognitive function, and dementia in older persons: the Cardiovascular Health Study. Stroke 2007; 38:2041-2047.
23. Guo L, Duggan J, Cordeiro MF: Alzheimer's disease and retinal neurodegeneration. Curr Alzheimer Res 2010; 7:3-14.
24. van Koolwijk LM, Despriet DD, Van Duijn CM, Oostra BA, van Swieten JC, de Koning I, Klaver CC, Lemij HG: Association of cognitive functioning with retinal nerve fiber layer thickness. Invest Ophthalmol Vis Sci 2009; 50: 4576-4580.